Xiaohui (Sophia) Xu
Xiaohui (Sophia) Xu has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Alok Rathi
BioAgilytix Boston, Boston, Massachusetts, USA
1 shared publication - Andrea A. Romeo
Roche Pharma Research and Early Development Basel Switzerland
1 shared publication - Chongwoo Yu
US Food and Drug Administration, Silver Spring, Maryland, USA
1 shared publication - Daniela Fraier
Pharmaceutical Sciences F. Hoffmann‐La Roche Ltd Basel Switzerland
1 shared publication - David G. Rizzo
AbbVie Inc., North Chicago, Illinois, USA
1 shared publication - David S. Wagner
AbbVie Inc. North Chicago Illinois USA
1 shared publication
Latest Publications
- Open Access
- 1 July 2026
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (4)
Updated Recommendations for the Bioanalysis of Antibody–Drug Conjugates (ADC) from the ADC working group of the AAPS Bioanalytical Community
Antibody–drug conjugates (ADCs) represent a rapidly evolving therapeutic modality, combining the selective targeting of monoclonal antibodies with highly potent small molecule payloads. Their inherent structural complexity demands a sophisticated and multi-faceted bioanalytical approach spanning preclinical discovery through late-stage clinical development. This white paper, developed by the ADC Working Group of the AAPS bioanalytical community, comprising over 100 members from industry, contract research organizations (CROs), and regulatory agencies, provides updated recommendations for ADC bioanalysis. Building upon the foundational 2013 AAPS position paper and recent publications governing regulatory frameworks on PK considerations, this work addresses advances in bioanalytical quantitation strategies for total antibody (tAb), conjugated ADC, free (unconjugated) payload, and drug-to antibody ratio (DAR); novel immunogenicity assessment considerations; soluble target interference; critical reagent lifecycle management; payload-specific stability requirements; cross-validation strategies; and regulatory considerations. The recommendations presented herein reflect over a decade of scientific progress and are designed to serve as a comprehensive, empirically validated, and industry aligned bioanalytical framework for contemporary ADC drug development.
- 1 July 2026
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (4)
Open AccessUpdated Recommendations for the Bioanalysis of Antibody–Drug Conjugates (ADC) from the ADC working group of the AAPS Bioanalytical Community
Antibody–drug conjugates (ADCs) represent a rapidly evolving therapeutic modality, combining the selective targeting of monoclonal antibodies with highly potent small molecule payloads. Their inherent structural complexity demands a sophisticated and multi-faceted bioanalytical approach spanning preclinical discovery through late-stage clinical development. This white paper, developed by the ADC Working Group of the AAPS bioanalytical community, comprising over 100 members from industry, contract research organizations (CROs), and regulatory agencies, provides updated recommendations for ADC bioanalysis. Building upon the foundational 2013 AAPS position paper and recent publications governing regulatory frameworks on PK considerations, this work addresses advances in bioanalytical quantitation strategies for total antibody (tAb), conjugated ADC, free (unconjugated) payload, and drug-to antibody ratio (DAR); novel immunogenicity assessment considerations; soluble target interference; critical reagent lifecycle management; payload-specific stability requirements; cross-validation strategies; and regulatory considerations. The recommendations presented herein reflect over a decade of scientific progress and are designed to serve as a comprehensive, empirically validated, and industry aligned bioanalytical framework for contemporary ADC drug development.
- 12 March 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 115 (5) , 939-953
Metabolite Bioanalysis in Drug Development: Recommendations from the IQ Consortium Metabolite Bioanalysis Working Group
The intent of this perspective is to share the recommendations of the International Consortium for Innovation and Quality in Pharmaceutical Development Metabolite Bioanalysis Working Group on the fit‐for‐purpose metabolite bioanalysis in support of drug development and registration. This report summarizes the considerations for the trigger, timing, and rigor of bioanalysis in the various assessments to address unique challenges due to metabolites, with respect to efficacy and safety, which may arise during drug development from investigational new drug (IND) enabling studies, and phase I, phase II, and phase III clinical trials to regulatory submission. The recommended approaches ensure that important drug metabolites are identified in a timely manner and properly characterized for efficient drug development.
- 12 March 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 115 (5) , 939-953
Metabolite Bioanalysis in Drug Development: Recommendations from the IQ Consortium Metabolite Bioanalysis Working Group
The intent of this perspective is to share the recommendations of the International Consortium for Innovation and Quality in Pharmaceutical Development Metabolite Bioanalysis Working Group on the fit‐for‐purpose metabolite bioanalysis in support of drug development and registration. This report summarizes the considerations for the trigger, timing, and rigor of bioanalysis in the various assessments to address unique challenges due to metabolites, with respect to efficacy and safety, which may arise during drug development from investigational new drug (IND) enabling studies, and phase I, phase II, and phase III clinical trials to regulatory submission. The recommended approaches ensure that important drug metabolites are identified in a timely manner and properly characterized for efficient drug development.